Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 10/20 | 0.39 |
| ▸ | PREP | P48147 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6234921 | 1.00 | DPP4 (0.39) | DPP4PREPCHRM2CHRM4CHRM5 | |
| SCHEMBL3526616 | 1.00 | DPP4 (0.39) | DPP4PREPCHRM2CHRM4CHRM5 | |
| SCHEMBL185999 | 0.94 | CHRM2 (0.39) | DPP4CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL6231704 | 0.87 | — | — | |
| SCHEMBL5015154 | 0.84 | FASN (0.41) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL25095482 | 0.82 | CHRM2 (0.54) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL28541669 | 0.82 | DPP4 (0.41) | DPP4PREPCHRM2CHRM4CHRM5 | |
| SCHEMBL28541668 | 0.82 | DPP4 (0.41) | DPP4PREPCHRM2CHRM4CHRM5 | |
| SCHEMBL27274626 | 0.82 | HPGD (0.47) | DPP4 | |
| SCHEMBL25180369 | 0.82 | CHRM2 (0.54) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024129763-A1 | MODULATORS OF TNF-α ACTIVITY | FORWARD THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| CN-117858877-A | C-linked inhibitors of ENL/AF9 YEATS | 桥梁药品有限公司 | 2024-04-09 | — | — | CN | disclosed |
| US-11939328-B2 | Quinoline compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2024-03-26 | — | — | US | disclosed |
| EP-4337662-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | Bridge Medicines (US) | 2024-03-20 | — | — | EP | disclosed |
| WO-2024027762-A1 | FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海艾力斯医药科技股份有限公司 | 2024-02-08 | — | — | WO | disclosed |
| US-20230364070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ANTARES THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| CN-116997549-A | Pyrrolo [3,2-C ] pyridin-4-one derivatives for the treatment of cancer | 蝎子疗法股份有限公司 | 2023-11-03 | — | — | CN | disclosed |
| US-11746095-B2 | Inhibtors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2023-09-05 | — | — | US | disclosed |
| EP-4217070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Scorpion Therapeutics, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230174555-A1 | NAPHTHYRIDINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2023-06-08 | — | — | US | disclosed |
| US-20070244119-A1 | 1,3,5-Substituted Phenyl Derivative Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LLC | 2007-10-18 | — | — | US | disclosed |
| EP-1740559-A1 | 1,3,5-SUBSTITUTED PHENYL DERIVATIVE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Merck & Co., Inc. (US) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005103020-A1 | 1,3,5-SUBSTITUTED PHENYL DERIVATIVE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| WO-2005007083-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-01-27 | — | — | WO | disclosed |
| US-6143761-A | 2,3-dihydrofuro [3,2-β]pyridin, preparation and application thereof in therapy | SANOFI-SYNTHELABO (FR) | 2000-11-07 | — | — | US | disclosed |
| EP-0971929-A1 | 2,3-DIHYDROFURO 3,2-$i(b)]PYRIDIN, PREPARATION AND APPLICATION THEREOF IN THERAPY | SANOFI-SYNTHELABO (FR) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998042713-A1 | 2,3-DIHYDROFURO[3,2-b]PYRIDIN, PREPARATION AND APPLICATION THEREOF IN THERAPY | SANOFI-SYNTHELABO (FR) | 1998-10-01 | — | — | WO | disclosed |
| US-5128483-A | CNS Disorders | AMERICAN CYANAMID COMPANY (US) | 1992-07-07 | — | — | US | disclosed |
| US-5001142-A | Alzheimer's disease | AMERICAN CYANAMID COMPANY (US) | 1991-03-19 | — | — | US | disclosed |
| EP-0408879-A2 | 1-Substituted-2-(3-amino-1-propynyl)-pyrrolidine derivatives | AMERICAN CYANAMID COMPANY (US) | 1991-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244119-A1 | 1,3,5-Substituted Phenyl Derivative Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease | BACE1, BACE2, PSEN1 | DPP4 57/4885PREP 17/4885CHRM2 3124/4885 |
| US-20230174555-A1 | NAPHTHYRIDINE COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | DPP4 3760/4885PREP 2315/4885CHRM2 4866/4885 |
| US-20230364070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ERBB2, EGFR, ERBB3 | DPP4 2949/4885PREP 2056/4885CHRM2 1569/4885 |
| US-11746095-B2 | Inhibtors of RAF kinases | RAF1, BRAF, ARAF | DPP4 4369/4885PREP 2469/4885CHRM2 4799/4885 |
| US-11939328-B2 | Quinoline compounds as inhibitors of KRAS | KRAS, NRAS, HRAS | DPP4 3819/4885PREP 3110/4885CHRM2 4782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.